<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Little is known about factors contributing to disease-evolution in early-phase <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In this article, low erythropoietin (EPO) production is discussed as a 'non-oncogenic' co-factor responsible for disease-manifestation in a group of patients with low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The hypothesis is based on the observations that (i) individuals with bone marrow <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-related karyotypes but relatively high EPO levels may present without <z:hpo ids='HP_0001903'>anemia</z:hpo> and thus without frank <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> over years, (ii) several elderly patients with idiopathic <z:hpo ids='HP_0001903'>anemia</z:hpo> are low EPO producers and their <z:hpo ids='HP_0001903'>anemia</z:hpo> can be corrected with EPO therapy, and (iii) the well-known fact that low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients typically respond to EPO therapy when they have low endogenous EPO levels </plain></SENT>
</text></document>